Sentinel lymph node biopsy in low risk settings - 16/08/17
Abstract |
Background |
Sentinel lymph node biopsy (SLNB) should be performed in patients with ductal carcinoma in situ (DCIS) undergoing mastectomy. Yet, the same logic is controversial in the setting of prophylactic mastectomy.
Methods |
Surgeons were surveyed as to their practices. Statistical analyses were performed to identify associated factors.
Results |
238 surgeons responded to the survey. 73.1% of respondents stated they would always perform SLNB in the setting of mastectomy for DCIS, but only 6.6% would always do so in the prophylactic setting. While generally perceived that the rate of SLN positivity in the setting of pure DCIS and prophylactic mastectomy was <5% (96.9% and 99.5%, respectively), 61.8% of surgeons who reported “always” performing SLNB in the setting of DCIS treated with mastectomy stated they “never” performed a SLNB for prophylactic mastectomy.
Conclusion |
SLNB practice patterns for these low risk settings are disparate. Consensus is required to rationalize practice.
Le texte complet de cet article est disponible en PDF.Keywords : SLNB, Low risk, Mastectomy, DCIS, Prophylactic mastectomy
Plan
Vol 214 - N° 3
P. 489-494 - septembre 2017 Retour au numéro
Article précédent
- The role of computed tomography in following up pediatric skull fractures
- Maria Zulfiqar, Stacy Kim, Jin-Ping Lai, Yihua Zhou
- The safety of same-day breast reconstructive surgery: An analysis of short-term outcomes
- Erin Cordeiro, Toni Zhong, Timothy Jackson, Tulin Cil
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?